7.64
Schlusskurs vom Vortag:
$7.80
Offen:
$7.77
24-Stunden-Volumen:
22,094
Relative Volume:
0.31
Marktkapitalisierung:
$434.74M
Einnahmen:
$154.57M
Nettoeinkommen (Verlust:
$15.07M
KGV:
28.30
EPS:
0.27
Netto-Cashflow:
$10.92M
1W Leistung:
+1.06%
1M Leistung:
+6.11%
6M Leistung:
+1.46%
1J Leistung:
+29.93%
Kamada Ltd Stock (KMDA) Company Profile
Vergleichen Sie KMDA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
KMDA
Kamada Ltd
|
7.64 | 434.74M | 154.57M | 15.07M | 10.92M | 0.27 |
![]()
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-21 | Eingeleitet | The Benchmark Company | Buy |
2024-07-03 | Eingeleitet | Stifel | Buy |
2018-02-02 | Eingeleitet | Chardan Capital Markets | Buy |
Kamada Ltd Aktie (KMDA) Neueste Nachrichten
What analysts say about Kamada Ltd. stockExceptional growth trajectory - jammulinksnews.com
Is Kamada Ltd. a good long term investmentBreakthrough capital growth - jammulinksnews.com
What makes Kamada Ltd. stock price move sharplyHigh Potential Safe Trades - Newser
What drives Kamada Ltd. stock priceConsistent high-performance stocks - jammulinksnews.com
Kamada Ltd. Stock Analysis and ForecastOutstanding yields - jammulinksnews.com
Why Kamada Ltd. stock attracts strong analyst attentionFree Real-Time Trading Opportunities - Newser
How Kamada Ltd. stock performs during market volatilityProfitable Yet Secure Picks - Newser
Emphysema Pipeline 2025: MOA, ROA, and Clinical Trial Insights - openPR.com
Emphysema Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Kamada, Ltd., Hoffmann-La Roche, Aeris Therapeutics, Grifols Therapeutics, Sanofi - The Globe and Mail
Emphysema Pipeline 2025: MOA, ROA, And Clinical Trial Insights Explored By Delveinsight Kamada, Ltd., Hoffmann-La Roche, Aeris Therapeutics, Grifols Therapeutics, Sanofi - MenaFN
Is Kamada (KMDA) Stock Undervalued Right Now? - Nasdaq
Kamada confirms continuous business operations despite recent events in Middle East - MSN
Should Value Investors Buy Kamada (KMDA) Stock? - Yahoo Finance
Kamada Confirms Continuous Global Business Operations and - GlobeNewswire
Kamada Ensures Global Operations Amid Middle East Tensions - TipRanks
Kamada confirms continuous business operations despite Middle East events - TipRanks
Kamada Confirms No Supply Disruptions: How Israeli Biotech Giant Safeguards Global Product Availability - Stock Titan
Plasma Therapeutics Market Revenue to Attain USD 46.46 Bn by 2033 - Precedence Research
Kamada Reports Strong Q1 2025 Growth with Plasma Business Expansion and Key Milestones - citybuzz -
Implied Volatility Surging for Kamada Stock Options - Yahoo Finance
Kamada Intensifies Efforts to Highlight CYTOGAM's Role in Combatting CMV in Organ Transplant Patients - citybuzz -
Kamada Wants To Do More For Organ Transplant Patients, Increases Efforts To Build Awareness Of Its CMV Treatment CYTOGAM - FinancialContent
Millennium Management LLC Sells 36,872 Shares of Kamada Ltd. (NASDAQ:KMDA) - Defense World
Are Investors Undervaluing Kamada (KMDA) Right Now? - Yahoo Finance
Alpha-1 Antitrypsin Deficiency Market: Epidemiology, - openPR.com
Kamada (NASDAQ:KMDA) Stock Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Kamada (NASDAQ:KMDA) Stock Rating Upgraded by Wall Street Zen - Defense World
Kamada's (TLV:KMDA) Solid Earnings Are Supported By Other Strong Factors - simplywall.st
Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm - The Manila Times
HC Wainwright Issues Optimistic Outlook for Kamada Earnings - Defense World
Sidoti Csr Has Optimistic Outlook of Kamada FY2025 Earnings - Defense World
Kamada’s (KMDA) Buy Rating Reiterated at Benchmark - Defense World
Kamada Ltd. (NASDAQ:KMDA) Q1 2025 Earnings Call Transcript - MSN
Finanzdaten der Kamada Ltd-Aktie (KMDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):